PHAEDRA is an ongoing study following a group of people ('cohort') who were enrolled in the very early period following seroconversion ('primary HIV infection'). The study aim is to explore and characterise some of the immune system responses to HIV in the period following infection, to look at the effects of treatment and to identify any particular factors that may influence the progression of HIV disease. The study will also monitor the transmission of drug-resistant HIV.
This study will investigate the impact hepatitis B has on liver disease in people who also have HIV and are currently on HIV treatments. It will also monitor to see if anyone develops any resistance to their HIV treatments because of their hepatitis B.
It involves six-monthly visits and physical examinations to track your health progression over five years
This study is looking at how our immune system functions when we are coinfected with both HIV and either hepatitis B or C.
It might show us how some people can clear hepatitis from their system when they're on treatment while others can when they're not.
The purpose of this substudy was to collect blood samples from SMART study participants for use in future Community Programs for Clinical Research on AIDS (CPCRA) studies investigating the link between human genetic factors and clinical outcome data.
This study enrolled individuals who participated in the SMART study. Participants provided one blood sample. Individual test results from future blood analyses will not be provided to a patient unless they may have profound health implications for that patient.
This information was retrieved from the Treataware website (www.treataware.info) on 20 Nov 2008. For further information, please consult the website or call the NAPWA office on 02 8568 0300.